Dissolving Microneedles Loaded with Lipid Nanoparticles for Co-Delivery of siTNF-α and Dexamethasone as a Dual-Action Therapy for Psoriasis
ACS Applied Materials & Interfaces · 2026
DOI: 10.1021/acsami.6c12530 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2026. Verfasst von Yaxin Cheng und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Mechanism and Quality of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau999078, China. Hauptthemen laut MEDLINE: Dexamethasone, Nanoparticles, Psoriasis, Tumor Necrosis Factor-alpha. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Research Grants Council, University Grants Committee, Fundo para o Desenvolvimento das Ciências e da Tecnologia, Fundo para o Desenvolvimento das Ciências e da Tecnologia.
Abstract (Originalsprache)
Psoriasis, a chronic inflammatory skin disease, presents treatment challenges including systemic side effects and inadequate topical drug delivery. Herein, we developed a hyaluronic acid (HA)-based dissolving microneedle platform delivering tumor necrosis factor-alpha (TNF-α)-targeting small interfering RNA (siRNA) and dexamethasone co-loaded within dual-functional lipid nanoparticles (LNPs). This LNP design innovatively integrates dexamethasone into its lipid structure, combined with siRNA to enhance stability and anti-inflammatory efficacy while minimizing immunogenicity. The HA microneedles enabled localized, minimally invasive delivery of LNPs into psoriatic lesions. Physicochemical characterization confirmed stable co-loading of siRNA and dexamethasone, with dexamethasone enhancing both LNP stability and siRNA protection. In-vitro studies demonstrated a dual-action mechanism: Dexamethasone suppressed inflammatory signaling pathways while siRNA silenced TNF-α expression, leading to superior inhibition of key proinflammatory cytokines. In a psoriasis-like mouse model, this combinatorial strategy significantly reduced disease severity, normalized epidermal hyperplasia, and decreased immune cell infiltration compared to single-agent therapies. The structural incorporation of dexamethasone within LNPs represents a critical advancement, enabling localized immunomodulation that mitigates systemic risks while amplifying TNF-α suppression. This integrated approach achieved sustained therapeutic effects with reduced dosing frequency. By co-delivering gene silencing and pharmacological agents via a patient-compliant dissolving microneedle system, our work establishes a precision medicine strategy for psoriasis management, addressing both inflammatory pathways and drug delivery limitations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Mechanism and Quality of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau999078, China.
- Department of Biomedical Engineering, College of Biomedicine, City University of Hong Kong, Hong Kong SAR, China.
- School of Pharmacy and Food Engineering, Wuyi University, Jiangmen529020, China.
- Department of Pharmacy and Pharmaceutical Sciences, Faculty of Medicine, University of Macau, Macau999078, China.
- Guangdong-Hong Kong-Macao Joint Laboratory for New Drug Screening, University of Macau, Macau999078, China.
ORCID-Profile: Chenjie Xu, Guodong Zhu, Ying Zheng
Förderung
- Research Grants Council, University Grants Committee
- Fundo para o Desenvolvimento das Ciências e da Tecnologia
- Fundo para o Desenvolvimento das Ciências e da Tecnologia
Zitieren
APA
Cheng, Y., Han, Y., Gu, X., Liu, Y., Tang, Y., Gao, J., Xu, C., Zhu, G., & Zheng, Y. (2026). Dissolving Microneedles Loaded with Lipid Nanoparticles for Co-Delivery of siTNF-α and Dexamethasone as a Dual-Action Therapy for Psoriasis. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.6c12530
Vancouver
Cheng Y, Han Y, Gu X, Liu Y, Tang Y, Gao J, et al. Dissolving Microneedles Loaded with Lipid Nanoparticles for Co-Delivery of siTNF-α and Dexamethasone as a Dual-Action Therapy for Psoriasis. ACS Applied Materials & Interfaces. 2026. doi:10.1021/acsami.6c12530
BibTeX
@article{Cheng2026,
author = {Cheng, Yaxin and Han, Yunfeng and Gu, Xueying and Liu, Yulu and Tang, Yidan and Gao, Jie and Xu, Chenjie and Zhu, Guodong and Zheng, Ying},
title = {Dissolving Microneedles Loaded with Lipid Nanoparticles for Co-Delivery of siTNF-α and Dexamethasone as a Dual-Action Therapy for Psoriasis},
journal = {ACS Applied Materials & Interfaces},
year = {2026},
doi = {10.1021/acsami.6c12530}
}
EUVIMED